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Hodgkin’s disease is divulging its secrets at last. Despite the
fact that Hodgkin’s disease was the first lymphoma to be rec-
ognized as a distinct clinical entity (1), it has proved to be one
 
of the most difficult lymphomas to approach molecularly.
The clonal, malignant Hodgkin/Reed-Sternberg (H/RS)
cells of Hodgkin’s disease represent 
 
,
 
1% of the cells in an
involved lymph node and are characteristically surrounded
by a mixture of granulocytes, plasma cells, and T cells. Al-
though several cell lines have been derived from patients
 
with Hodgkin’s disease, it has been difficult to prove, in
most cases, that the cell lines are clonally related to the H/RS
cells of the patients. Therefore, molecular approaches to the
etiology and pathogenesis of Hodgkin’s disease have relied
on single cell micromanipulation of H/RS cells coupled with
PCR amplification of RNA and genomic DNA. These tech-
niques have shed considerable light on the cellular origins
of Hodgkin’s disease through analysis of the antigen recep-
tor genes of H/RS cells (2). These techniques have also led
to the identification of the first recurrent molecular abnor-
mality of H/RS cells: mutations in the I
 
k
 
B
 
a
 
 gene (3, 4;
and, in this issue, Jungnickel et al. [5]). This finding specifi-
cally implicates the nuclear factor 
 
k
 
B (NF-
 
k
 
B) transcription
factor signaling pathway in the pathogenesis of Hodgkin’s
disease. Once revealed, this association seems quite natural
given the intense inflammatory component of Hodgkin’s
lymphoma lesions and the central role that NF-
 
k
 
B plays in
the normal regulation of inflammatory responses (6).
 
Cellular Origins of Hodgkin’s Disease.
 
The normal cellu-
lar counterpart of the H/RS cell has long been enigmatic
due to the promiscuous expression in H/RS cells of mark-
ers that are normally expressed in distinct hematopoietic
lineages. H/RS cells can variably express T cell markers
(e.g., CD2, CD4, granzyme B), B cell markers (e.g., CD19,
CD20), and myeloid markers (e.g., CD15, c-fms) (7, 8).
Within the lymphoid lineages, the most lineage-specific mo-
lecular events involve rearrangement and mutation of the
antigen receptor genes. Analysis of micromanipulated H/RS
cells from nodular sclerosis Hodgkin’s disease, the most
common subtype, revealed that most patients had a clonal
rearrangement of the V, D, and J segments of the IgH
chain locus in the H/RS cells, indicating that these cells
descended from B lymphocytes (2). Sequence analysis of
the rearranged VDJ regions from these H/RS cells demon-
strated a high load of somatic mutations, often resulting in
nonfunctional Ig V regions (9). Inasmuch as somatic hyper-
mutation of Ig genes occurs characteristically in germinal
centers of secondary lymphoid organs (10), these findings
suggested that H/RS cells arise from germinal center B
cells or from B cells at a later stage of differentiation.
Most recently, evidence has accumulated that the initial
transforming event in Hodgkin’s disease occurs within the
germinal center B cell itself (11, 12). This view arose from
analysis of rare patients with “composite lymphomas” in
which Hodgkin’s disease coexists with a non-Hodgkin’s
lymphoma (NHL). In these patients, the H/RS cells and
the NHL cells had identical VDJ rearrangements at the IgH
chain locus and also shared certain somatic mutations within
the VDJ region. The H/RS and NHL cells both accumu-
lated additional somatic mutations that were not shared by
the other cell type. As previously observed in other NHL
cases, the VDJ regions of the NHL cells of these patients
showed a pattern of ongoing somatic mutation, suggesting
that the initial transforming event(s) occurred within the
germinal center microenvironment. Since the H/RS cells
and the NHL cells were clonally related, the simplest ex-
planation of these findings is that the initial transforming
event occurred in a germinal center B cell that was the pre-
cursor of both the NHL cells and the H/RS cells. From this
perspective, it is also clear that the H/RS cells and/or the
NHL cells in these patients must have acquired secondary
molecular lesions that account for the strikingly different
phenotypes of these two cell types.
An additional complication is that the four histologically
distinct subtypes of Hodgkin’s disease (nodular sclerosis,
nodular lymphocyte–predominant, mixed cellularity, and
lymphocyte depletion) may well represent diseases with sep-
arate molecular and cellular etiologies. Nodular lympho-
cyte–predominant Hodgkin’s disease is also derived from a
B cell, as indicated by clonal VDJ rearrangements of the
IgH chain locus in the malignant lymphocytic and histio-
cytic (L&H) cells of this disease (13–15). The VDJ regions
of L&H cells show a pattern of somatic mutation that sug-
gests that mutations continued to accumulate after the ini-
tial transforming event and were positively selected by anti-
gen. L&H cells express BCL-6 (16), a transcriptional repressor
protein characteristically expressed in germinal center B
cells (17). Taken together, these data suggest that the L&H
cells of nodular lymphocyte–predominant Hodgkin’s dis-
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ease are derived from germinal center B cells and retain at
least part of the germinal center B cell phenotype.
In contrast, the H/RS cells of nodular sclerosis Hodgkin’s
disease frequently lack BCL-6 expression (18) and do not
show evidence of ongoing somatic hypermutation of their Ig
genes (2). Further differences between germinal center B cells
and H/RS cells were uncovered during high-throughput ex-
pressed sequence tag (EST) sequencing of cDNA libraries
prepared from individual H/RS cells (19). Many established
germinal center B cell markers, including CD10 (20), a-myb
(21), and 8-oxoguanine-DNA glycosylase (OGG-1 [22]),
were not observed during sequencing of the H/RS libraries
but were repeatedly observed in a library derived from ton-
sillar germinal center and memory B cells (19). Thus, although
the initial transforming event leading to an H/RS cell may
occur in a germinal center B cell, much of the biology of
this stage of B cell differentiation does not appear to be re-
tained by this malignant cell.
With the emerging view that most H/RS cells derive
from germinal center B cells, what accounts for the ectopic
expression of T cell and myeloid markers in some cases? In
this issue, Müschen et al. (23) examined three Hodgkin’s
disease cases in which the H/RS cell was found to express
cytotoxic T cells markers (granzyme B, T cell intracellular
antigen 1 [TIA-1], and/or perforin) by immunohistochem-
istry. In two cases, the IgH chain loci had VDJ rearrange-
ments and the TCR-
 
b
 
 locus was in germline configuration.
Surprisingly, the third case had clonal VDJ rearrangements
of the TCR-
 
b
 
 locus and germline configuration of the IgH
chain locus. This observation, together with the fact that
some Hodgkin’s cell lines also have TCR gene rearrange-
ments (8), demonstrates that classical nodular sclerosis
Hodgkin’s disease can, in rare cases, be derived from a T cell.
Therefore, in these cases, the expression of the cytotoxic T
cell markers by the H/RS cells may not be ectopic after all.
Nonetheless, the aberrant expression of T lineage mark-
ers in the other two cases remains unexplained and suggests
that global changes in gene expression patterns are a conse-
quence of the transforming events leading to Hodgkin’s
disease. Promiscuous expression of lineage markers is a fea-
ture of uncommitted stem cells (24). Of note in this regard
is the fascinating, stem cell–like behavior of pro-B cells
from mice deficient in Pax5, a key differentiation factor in
the B cell lineage (25). Pax5
 
2
 
/
 
2
 
 pro-B cells fail to differen-
tiate further along the B cell lineage and instead behave as
uncommitted hematopoietic progenitor cells (25). Intrigu-
ingly, Pax5
 
2
 
/
 
2
 
 pro-B cells aberrantly express genes from
many hematopoietic lineages, including c-fms and perforin,
two of the genes aberrantly expressed in H/RS cells. Thus,
it may be worth investigating whether the transforming
events of H/RS cells interfere with the expression and/or
function of transcription factors that are involved with cell
fate and commitment decisions in the B cell lineage.
 
Molecular Origins of Hodgkin’s Disease.
 
The first indica-
tion of a role for NF-
 
k
 
B in Hodgkin’s disease came with
the observation that several Hodgkin’s disease cell lines and
primary H/RS cells from one patient had constitutive NF-
 
k
 
B DNA binding activity in the nucleus (26). The NF-
 
k
 
B
 
family of transcription factors consists of homo- and het-
erodimers of a variety of gene products related to the v-rel
oncoprotein (6). Most cells do not have nuclear NF-
 
k
 
B
because one or more inhibitory proteins belonging to the
inhibitor of NF-
 
k
 
B (I
 
k
 
B) family sequester the NF-
 
k
 
B fac-
tors in the cytoplasm. A wide variety of cellular stimuli
leads to the phosphorylation, ubiquitination, and subse-
quent degradation of I
 
k
 
B, allowing NF-
 
k
 
B factors to travel
to the nucleus. The situation is a bit more complex in ma-
ture B cells in that the NF-
 
k
 
B1/c-rel heterodimer can be
constitutively present in the nucleus while the NF-
 
k
 
B1/
relA heterodimer is inducible (27, 28). Hodgkin’s cell lines
resembled mature B cells in having nuclear NF-
 
k
 
B1/c-rel
but differed from mature B cells by the constitutive pres-
ence of NF-
 
k
 
B1/relA in the nucleus (26).
A priori, the mechanisms underlying this phenomenon
could include constitutive activity of kinases upstream of
I
 
k
 
B, mutation or loss of I
 
k
 
B, or modification of NF-
 
k
 
B
rendering it insensitive to inhibition by I
 
k
 
B. Several reports
now show that mutation of the I
 
k
 
B
 
a
 
 gene is the culprit in
a subset of Hodgkin’s cases (3–5). In two Hodgkin’s disease
cell lines, L428 and KM-H2, one allele of I
 
k
 
B
 
a
 
 is deleted
and the other allele has a deletion or point mutation which
results in a truncated I
 
k
 
B
 
a
 
 protein lacking the COOH ter-
minus. No I
 
k
 
B
 
a
 
 protein could be observed in KM-H2,
suggesting that the severely shortened protein from the
mutated allele is unstable. The truncated I
 
k
 
B
 
a
 
 protein in
L428 cells was stable but was unable to associate with NF-
 
k
 
B
heterodimers. Thus, the I
 
k
 
B
 
a
 
 mutations and deletions in
these cell lines made the cells functionally null for I
 
k
 
B
 
a
 
activity.
Since these Hodgkin’s disease cell lines were established
from treated patients late in the natural history of the dis-
ease, it was important to determine whether I
 
k
 
B
 
a
 
 alter-
ations are clonal events that occur in the H/RS cells of un-
treated patients. Definitive proof that this is the case came
from one untreated Hodgkin’s case in which all H/RS cells
that were micromanipulated from a lymph node biopsy
contained two different mutant I
 
k
 
B
 
a
 
 alleles, each resulting
in a COOH-terminal truncation of the protein (5). In the
19 patients studied thus far, 5 had truncating mutations of
I
 
k
 
B
 
a
 
 on at least 1 allele (3–5).
However, most Hodgkin’s disease cell lines and patients
apparently have wild-type I
 
k
 
B
 
a
 
 alleles and express I
 
k
 
B
 
a
 
protein. Nonetheless, the NF-
 
k
 
B pathway may also play a
role in these cases. For example, some Hodgkin’s disease
cell lines have wild-type I
 
k
 
B
 
a
 
 alleles yet have constitutive
nuclear NF-
 
k
 
B1/relA DNA binding complexes (29). In
such cases, constitutive activity of I
 
k
 
B kinases, leading to
rapid degradation of I
 
k
 
B
 
a
 
, appears to account for the pres-
ence of NF-
 
k
 
B in the nucleus (29). Although the cytokines
secreted by the Hodgkin’s disease cell lines can induce nu-
clear NF-
 
k
 
B (29), the possibility of molecular defects in the
components of the I
 
k
 
B kinase cascade should be investi-
gated. Since the H/RS cells of 17–41% of Hodgkin’s dis-
ease patients harbor EBV (30), the EBV-encoded protein
latent membrane protein 1 (LMP-1) may activate NF-
 
k
 
B
in these cases by promoting I
 
k
 
B
 
a
 
 turnover (31). Finally, 
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three TNF family receptor–ligand pairs have the potential
to activate NF-
 
k
 
B in Hodgkin’s disease: CD40 present on
the H/RS cell may be engaged by CD40 ligand on the sur-
rounding T cells in the Hodgkin’s lesions (32), TNF-
 
a
 
produced by the H/RS cell may act in an autocrine fashion
via TNF-
 
a
 
 receptors (33), and CD30 on the H/RS cells
may be cross-linked by CD30 ligand on either the H/RS
cell or on surrounding cells (34).
What are the functional consequences of constitutive
nuclear NF-
 
k
 
B in H/RS cells? Many of the genes known
to be expressed in H/RS cells are also NF-
 
k
 
B target genes.
I
 
k
 
B
 
a
 
 itself is a well-documented NF-
 
k
 
B target gene that is
transcriptionally activated by NF-
 
k
 
B, resulting in a nega-
tive feedback loop that attenuates NF-
 
k
 
B signaling (35,
36). In the majority of Hodgkin’s disease cases, 10–90% of
the H/RS cells expressed high levels of I
 
k
 
B
 
a
 
 as judged by
immunohistochemistry (3). Other known NF-
 
k
 
B target
genes expressed in H/RS cells include intercellular adhesion
molecule 1 (ICAM-1), GM-CSF, IL-6, and TNF-
 
a
 
. Bar-
gou et al. (37) directly manipulated the NF-
 
k
 
B system in
several Hodgkin’s cell lines by overexpressing a dominant
negative version of I
 
k
 
B
 
a
 
 which cannot be inducibly de-
graded. As a consequence, these cell lines had decreased
nuclear NF-
 
k
 
B, decreased proliferation rates, an enhanced
apoptotic response to removal of serum from the culture
medium, and decreased ability to form tumors in immuno-
deficient mice (37). A role for NF-
 
k
 
B in cellular transfor-
mation of B cells was previously demonstrated by the trans-
location of NF-
 
k
 
B2 (38) and the amplification of c-rel (39)
in NHLs.
The antiapoptotic effects of NF-
 
k
 
B have been docu-
mented in many cell types (6), including mouse B cells
(40). The observation that H/RS cells contain nonfunctional
Ig genes suggests that they are derived from germinal cen-
ter B cells that should have been negatively selected (2), but
were rescued from apoptosis by aberrant NF-
 
k
 
B activation.
Indeed, these results raise the possibility that normal posi-
tive selection of germinal center B cells may involve tran-
sient activation of NF-
 
k
 
B after interaction of the B cell
with antigen-bearing follicular dendritic cells. Most impor-
tantly, though, these studies suggest that pharmacological
manipulation of the NF-
 
k
 
B system might have therapeutic
potential in Hodgkin’s disease. However, given the variety
of ways in which NF-
 
k
 
B can be activated in Hodgkin’s
disease, any therapeutic intervention will have to be tai-
lored to the particular molecular lesion in each patient.
 
Insights into Hodgkin’s Disease from Genomics.
 
Given the
likelihood that NF-
 
k
 
B activation is only one step in a mul-
tistep transformation process, how can we get clues to the
other pathways that may be aberrant in Hodgkin’s disease?
Increasingly, the answer to this question will come from
the emerging field of functional genomics. In particular,
genomic-scale gene expression profiling using DNA mi-
croarrays has the potential to transform our understanding
of human cancer (41, 42). This technology can simulta-
neously quantitate the expression of tens of thousands of
genes in parallel, giving biologists a bird’s eye view of the
molecular pathways that are engaged in a cancer cell. The
similarity of a cancer cell to a particular stage of normal dif-
ferentiation can be defined by the expression of scores of
lineage-restricted genes instead of the handful of markers
currently in use. Databases of genes that are responsive to
various cytokines, signal transduction pathways, or tran-
scription factors will soon help biologists deconvolute the
gene expression profiles of cancer cells. Eventually, genomic-
scale gene expression analysis may be used to guide cancer
patients to the therapies that are most appropriate to the sig-
naling pathways that are engaged in their particular tumors.
DNA microarrays of 950 genes were used to profile gene
expression in 2 Hodgkin’s cell lines, L428 and KM-H2
(43). The gene expression in each of these cell lines was
measured relative to the gene expression in a lymphoblas-
toid B cell line transformed with EBV. Since the LMP1
protein of EBV would be expected to activate NF-
 
k
 
B tar-
get genes in the lymphoblastoid cell line, the expression of
some NF-
 
k
 
B target genes in the Hodgkin’s cell lines may
have been missed by this analysis. Nevertheless, these mi-
croarray experiments revealed the expression of several
genes in the Hodgkin’s cell lines that could play important
and previously unrecognized roles in the pathophysiology
of this disease.
In particular, the cytokine IL-13 was found to be ex-
pressed in each of the Hodgkin’s disease cell lines studied,
and IL-13 expression was subsequently found in H/RS
cells of Hodgkin’s disease by in situ hybridization (43). This
important cytokine promotes T helper cell differentiation
to the Th2 phenotype (44) and can influence the survival
and/or proliferation of B cells (45, 46). The receptors for
IL-13 and IL-4 have two signaling chains in common and
thus can activate overlapping target genes (47). Interest-
ingly, the Hodgkin’s disease cell lines were also found to
express the E4BP4/NF-IL3, a gene that was previously
found to be an IL-4–regulated gene by DNA microarray
gene expression analysis and by subtractive hybridization
(41, 48). Thus, the expression of E4BP4/NF-IL3 may indi-
cate autocrine signaling by IL-13 in the Hodgkin’s disease
cell lines. E4BP4/NF-IL3 encodes a transcription factor
that prevents IL-3 withdrawal apoptosis (49) and thus could
conceivably enhance the survival of H/RS cells. Another
known IL-13 target gene, macrophage-derived chemokine
(MDC [50]), was repeatedly encountered during the high-
throughput sequencing of H/RS cell cDNA libraries (19),
further supporting the possibility of IL-13 autocrine signal-
ing in H/RS cells. MDC specifically attracts Th2 cells (51)
and thus may contribute to the inflammatory milieu sur-
rounding H/RS cells.
Intriguingly, neutralizing antibodies to IL-13 blocked
the proliferation of the HDLM-2 Hodgkin’s disease cell
line (43), again supporting an autocrine signaling model
and suggesting that IL-13 signaling could be attacked phar-
macologically to the benefit of Hodgkin’s disease patients.
Although speculative, there could be a relationship between
the antiproliferative effects resulting from IL-13 neutraliza-
tion and from overexpression of dominant negative I
 
k
 
B
 
a
 
.
The IL-13–stimulated transcription factor, signal transducer
and activator of transcription 6 (Stat6), interacts physically 
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with NF-
 
k
 
B, and these two transcription factors synergisti-
cally activate some target genes (52–54). Although IL-13
normally counteracts NF-
 
k
 
B by activating I
 
k
 
B
 
a
 
 transcrip-
tion (55, 56), this effect may be mitigated in H/RS cells by
mutations in the I
 
k
 
B
 
a
 
 gene or by constitutive degradation
of IkBa.
As with most DNA microarray gene expression studies,
these experiments identified a host of other differentially
expressed genes that suggest intriguing hypotheses requir-
ing further work. The host of cytokines that H/RS cells are
capable of secreting (8), exemplified by IL-13, IL-5, and
GM-CSF in this DNA microarray analysis, most likely ini-
tiate the intense inflammatory reaction surrounding H/RS
cells. It remains to be determined whether the NF-kB acti-
vation in H/RS cells is responsible for this cytokine expres-
sion and whether other signaling pathways are required in
addition. Another gene expressed in both Hodgkin’s dis-
ease cell lines, IFN regulatory factor 1 (IRF-1), encodes a
transcription factor that can cooperate with NF-kB in acti-
vating certain genes (e.g., IFN-b [57]) and thus may act
synergistically with the constitutive NF-kB in H/RS cells.
Two other overexpressed genes in Hodgkin’s disease cell
lines play important roles in other cancers: insulin-like
growth factor II (IGF-II) is an antiapoptotic factor that is
overexpressed during mouse pancreatic tumor progression
(58), and urokinase plasminogen activator is an important
prognostic marker in a variety of solid tumors that is likely
to regulate cancer cell metastasis (59). In the future, the ap-
plication of DNA microarray gene expression analysis to
micromanipulated H/RS cells will present a considerable
technical challenge, but will be well worth the effort. Cur-
rent first-line treatments of Hodgkin’s disease can cure
roughly 80% of patients with early disease and 60% of pa-
tients with advanced disease (60). If DNA microarray gene
expression analysis of H/RS cells could identify those pa-
tients who are likely to relapse, they could be offered early
high-dose therapy coupled with hematopoietic transplanta-
tion (60), or other therapies suggested by our growing
knowledge of the molecular lesions in Hodgkin’s disease.
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